Efficacy of Vaccine BNT162b2 (Pfizer-BioNTech) in Individuals with Waldenstrom's Macroglobulinemia and Follicular Lymphoma in Australia

Introduction Lymphoid malignancies are a risk factor for severe COVID-19. Vaccination with BNT162b2 protects the general population from severe disease, but recent studies have shown limited seroconversion after vaccination in patients with lymphoid malignancy. This reduced response is likely relate...

Descripción completa

Detalles Bibliográficos
Autores principales: Beaton, Brendan, Sasson, Sarah C, Rankin, Katherine, Raedemaeker, Juliette, Wong, Alexander, Hastak, Priyanka, Warden, Andrew, Ospina Stella, Alberto, Aggarwal, Anupriya, Caterson, Ian D, Phetsouphanh, Chansavath, Turville, Stuart, Kelleher, Anthony D, Brilot, Fabienne, Trotman, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
623.Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701644/
http://dx.doi.org/10.1182/blood-2021-149348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701644/
http://dx.doi.org/10.1182/blood-2021-149348

Ejemplares similares